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Abstract
Background: In Germany, vaccination against hepatitis B is recommended for infants, children and
adolescents since 1995 and for specific target groups since 1982. Little is known about knowledge
about viral hepatitis and attitudes toward hepatitis B vaccination-factors likely to influence vaccine
uptake.
Methods: In order to estimate vaccination coverage in adult target groups and in the overall adult
population and to assess knowledge and attitudes, we conducted a nationwide cross-sectional
telephone survey among 412 persons in November 2004. We defined participants as being
vaccinated if they reported at least one previous vaccination against hepatitis B.
Results: Vaccination coverage (vc) standardised for age, sex and residence was 29.6% in the
general population and 58.2% in target groups for hepatitis B vaccination. Particular gaps in vaccine
coverage were detected among health care workers (vc: 69.5%) and chronically ill persons (vc:
22.0%). Knowledge on risk factors and transmission was far below expectations, whereas the
acceptance of vaccination in the majority of the population (79.0%) was good.
Conclusion: We conclude that educational measures could lead to a higher vaccination uptake in
adult target groups.
Background
Worldwide, 300 to 420 million people are chronically
infected with Hepatitis B (HB), affecting 5–7% of the
worlds population [1,2]. About 2 billion people (nearly a
third of the world's population) had previous contact
with the hepatitis B virus, corresponding to past or current
infection with hepatitis B.
Globally, more than 500.000 persons per year die from
the consequences of chronic HB infection. Main modes of
transmission are contacts with infected blood or other
body fluids, for example during sexual intercourse. Verti-
cal transmission also occurs, unless the newborn is vacci-
nated.
Compared to the overall, worldwide seroprevalence of
markers for HB, in Germany seroprevalence is low: 5–8%
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of the general population had a past or current HB infec-
tion and 0.4–0.7% are carriers of HBs-antigen, indicating
acute or chronic infection, accounting for an estimated
number of 300.000 to 650.000 potentially infectious peo-
ple [3-6]. In 2004, 1260 cases of acute hepatitis B were
notified, corresponding to an annual incidence of 1.5
cases/100,000 inhabitants per year, with the highest age
group specific incidence in young adults [6]. At least 30%
of notified hepatitis B cases in 2003/2004 occurred in
unvaccinated people belonging to target groups [7].
In 1982, the Standing Committee on Vaccination Recom-
mendations in Germany (STIKO) recommended HB vac-
cination for people belonging to target groups, e.g. health
care workers or other persons with potential occupational
exposure to HB virus, travellers to high-prevalence-coun-
tries, people with chronic renal or liver disease, intrave-
nous drug users or men who have sex with men [8]. In
1995, the STIKO recommendation was expended for all
infants, children and adolescents to be vaccinated against
HB [8]. Vaccination coverage among children is deter-
mined at school entry.
In 2004, 84% of the 6 year-olds having their vaccination
documents available at school entry were fully vaccinated
against HB [9].
Populations in Germany at particular risk for hepatitis B
virus infection have been estimated to amount to 1.85
million healthcare workers, about 1 million men who
have sex with men, 100 000 injecting drug users, and
more than 50 000 haemodialysis patients [3]. However,
data on HB-vaccine coverage among these target groups is
sparse.
It is also unknown whether insufficient awareness and
knowledge of HB transmission and possible protective
measures may form a major obstacle in terms of following
to vaccination recommendations in target groups [10].
For a majority of the target groups such as for medical staff
the responsibility to immunise lies with employer's health
care providers. Nevertheless, there is no obligatory duty to
get immunised for medical staff so far. Thus, it can be con-
cluded that individual knowledge and perceived risk for
HB infection play a key role for vaccination uptake in
these groups.
In order to assess the current vaccination coverage in the
general population and to learn more about knowledge
on viral hepatitis and attitudes towards HB vaccination in
the adult population in Germany, particularly in target
groups for HB infection we initiated a cross-sectional
nationwide telephone survey.
Methods
We conducted a nationwide telephone survey on Novem-
ber 8th and 29th 2004, involving participants of a course
on interventional infectious disease epidemiology as
interviewers. We aimed for a sample size of 350 interview-
ees, according to calculations based on an estimated HB
vaccine coverage among target groups of 30% at a preci-
sion of +/- 1.7%.
We used an anonymised, standardised questionnaire con-
sisting of mainly closed questions regarding vaccination
coverage and knowledge about viral hepatitis symptoms,
transmission modes and existing prevention measures, as
well as the general attitude towards vaccination. Inter-
viewers were briefed and trained in advance of the survey.
Random telephone numbers following the method by
Gabler and Häder were used to contact interviewees [11].
This method for achieving equivalence of samples in
cross-national surveys allows a maximum inclusion
opportunity for all fixed telephone subscribers in Ger-
many.
We estimated the prevalence of having an indication for
HB vaccination amongst the population of 10%. In order
to reach a precision of at least 3% at an alpha level of
95%and a statistical power of 80% we calculated a mini-
mum sample size of 384 completed interviews.
We oversampled participants from East Germany (the
former German Democratic Republic), where only 17% of
the adult German population reside, in order to achieve
sufficient statistical power and to reduce random error.
All results relating to the entire country are given as stand-
ardised data (age group, sex and geographic origin),
whereas data referring to particular subgroups are dis-
played as raw numbers.
We standardized the results according to age groups (18–
29 years, 30–39 years, 40–49 years, 50–59 years, ? 60
years), sex and geographical origin (West or East Ger-
many). We assigned Berlin to West Germany. Standardisa-
tion was used for the overall population in Germany but
also for specific target groups for HB vaccination (such as
travellers, medical professionals etc.).
The National Bureau for Statistics in Germany provided us
with information on population density and structure in
West and East Germany as of 2003.
Every person of at least 18 years of age contacted and will-
ing to participate who understood and spoke German sat-
isfactorily was considered eligible. In order to avoid
selection bias, we inquired for the one member of theBMC Public Health 2008, 8:132 http://www.biomedcentral.com/1471-2458/8/132
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household fulfilling criteria of eligibility with the most
recent birth date and asked him or her to participate. If
only one person was present, we asked this person to par-
ticipate. Informed oral consent about the selection proc-
ess and data protection issues was obtained before every
interview.
We defined a participant as being "vaccinated" if he or she
reported at least one (lifetime) previous vaccination with
a HB vaccine. Persons who did not know whether they
had been vaccinated previously were considered as "not
vaccinated".
We defined three main target groups for HB vaccination in
accordance with current STIKO recommendations:
Persons with an occupational risk of HB infection (e.g.
health care workers, social workers)
Persons with a travel history to a high-prevalence country
for HB
Chronically ill, i.e. persons with an elevated risk for HB
infection or enhanced risk of morbidity, e.g. those with
chronic renal or liver disease
In addition to questions concerning the vaccination status
of interviewees, we gained information about their
knowledge concerning causative agents, modes of trans-
mission and measures of protection against viral hepatitis
and attitudes towards HB vaccination.
We processed and analysed data in EPI-Info 2002, version
4.02 April 2004 and SPSS Version 12.0. Besides descrip-
tive analyses, we conducted group comparisons, bivariate
analysis and a multivariate logistic regression (backward
elimination) in order to detect variables independently
associated with vaccination or knowledge about HB,
respectively.
In a first model, our outcome variable was "being vacci-
nated against HB", and we included those variables asso-
ciated with vaccination in the bivariate analysis with
either an alpha level of ? 0.05 or a plausible association
with the vaccination status.
A second model was designed in order to identify varia-
bles associated independently with "good knowledge"
about viral hepatitis. For these purposes, we created a
combined variable, indicating good knowledge as:
Knowing at least two of the three most important poten-
tial transmissions routes of HB virus (sexual transmission,
blood transfusion, needle sharing)
and
Knowing at least two correct answers on the three most
important protection measures (vaccination, condom
use, hygiene measures such as gloves and hand disinfec-
tion for caretakers of infected persons)
and
Recognizing at least three out of five hepatitis forms (Hep-
atitis A-E)
We included variables significantly associated with "good
knowledge" in the bivariate analysis at a p level of ? 0.05
or a plausible association with the outcome variable.
Consent on data protection had been obtained in advance
from the data security officer of the Robert Koch Institute.
Ethical approval was not considered as participation was
voluntary; we used anonymous data only and did not
apply any invasive procedures (such as biological sample
taking) on participants.
Results
Study population
Of 4864 computer generated random numbers dialled,
(which, according to the Gabler/Häder method applied
included an unknown proportion of non-existing num-
bers) we connected to 1431 (29.4%) eligible persons. Of
those, 412 persons (28.8%) participated in the survey, of
whom 241 participants (58%) resided in West-Germany
and 171 (42%) in East-Germany.
With a sample population of 412 interviewees who com-
pleted interviews we reached a precision of +/- 2.9% at an
alpha level of 95% and a statistical power of 80%.
One hundred forty three (59.3%) of West German partic-
ipants and 106 (62%) of East German participants were
female. Median age was 44 years in West Germany (range
18–99 years) and 46 years in East Germany (range 18–74
years).
Overall, 93/412 participants (22.9%) belonged to at least
one target group for HB vaccination, among them 59 from
the West (24.5% of all West German participants) and 34
from the East (19.9% of all East German participants). We
failed to obtain information on whether interviewees
belonged to a target group in 6/412 cases (1.5%).
Altogether, 49.1% of the participants belonging a target
group reported having had a risk related to travel, 45.1%
reported occupational risks and 14.9% stated they had a
risk related to chronic disease (multiple answers were
allowed).BMC Public Health 2008, 8:132 http://www.biomedcentral.com/1471-2458/8/132
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Vaccination coverage
Information on vaccination status was available in 406
persons (98.5% of participants): 26.3% (95% CI 19.9–
33.6) of East-German participants and 31.1% (95% CI
25.2–37.4) of West German participants were vaccinated
according to our definition.
After standardisation for sex, age group and residency
(West/East Germany), this corresponded to an overall HB
vaccination coverage of 29.6% (95% CI 23.3–34.4) in
Germany. A total of 55.7% of those vaccinated were
female (95% CI 46.5–64.7).
A total of 25.0% of participants belonged to at least one of
three target groups for HB vaccination (95% CI 20.7–
29.3). Of those, 58.2% (95% CI 47.9–67.7) were vacci-
nated according to our definition (table 1).
Median age for members of the target groups "travel risk",
"occupational risk" or "chronic disease" was 37, 31, and
46 years respectively.
A higher vaccination coverage among all vaccinated was
seen in persons with higher education levels (completed
high school) in comparison to those with lower education
levels (36.4% versus 25.7%, p < 0.05).
Of vaccinated participants, 41.2% reported having
received at least three doses, 4.6% reported having had 2
doses and 3.5% reported having had one dose of HB vac-
cine previously, whereas 49.1% did not recall the exact
number of doses they had received (2 cases missing).
Attitudes towards vaccination
151/171 (88.3%) participants from East Germany and
181/235 (77.0%) participants from West Germany had a
positive attitude towards vaccinations in general. This cor-
responds to a standardised percentage of 79.0% (95% CI
74.7–82.7) for the entire country.
Standardised results for Germany indicate that 76.7% of
the participants (95% CI 71.9–81.1) were generally aware
of the availability of a vaccine against HB. Nearly two
thirds (66.2%) believed in a good protective efficacy of
the vaccine (95% CI 60.1–71.8) (figure 1).
Knowledge about viral hepatitis, transmission modes and 
protective measures
HB was known best, but only 57.7% actively mentioned it
(table 2) when asked about different forms of hepatitis.
"Hepatitis B" could be named actively by 64% of partici-
pants with a secondary level school degree and by 93% of
participants with A-level degrees (p < 0.05).
Nearly 60% of the sample population identified HB as
being caused by a virus (figure 2). No significant differ-
ence in knowledge on the pathogen causing HB was
found between target groups versus those without explicit
indication for HB vaccination.
While the majority of interviewees realized that jaundice
is among the possible symptoms of HB infection, less
than half of them were aware that HB can cause liver can-
cer (table 3).
Regarding knowledge about possible clinical outcomes of
HB, there was no relevant difference between all target
groups for HB vaccination versus other population
groups. However, the subgroup of those occupationally at
risk compared to other population groups was more
aware of possible sequelae of HB such as liver cancer, liver
cirrhosis or liver failure (table 3).
Unprotected sexual intercourse was recognised as a risk
factor more frequently in target groups for HB vaccination
than in other participants (75.6% vs. 50.8%, p < 0.05),
whereas needle sharing and blood transfusion were iden-
tified as risk factors by all groups of participants.
Figure 3 gives an overview of knowledge about transmis-
sion modes for HB infection.
In the overall sample, 73.9% (95% CI 68.9–78.4) recog-
nised condoms as a protective measure to prevent HB.
Condoms were less well recognised as protective than HB
vaccination and hygiene measures. Figure 4 summarises
answers concerning knowledge about protective measures
to avoid HB.
Table 1: HB vaccination status according to target group, Germany. Standardised by age, sex and residence (East/West Germany), 
November 2004 (n = 412)
Target group Vaccination coverage (%) 95% Confidence Interval
Occupational risks 69.5 54.3 – 82.3
Travel to highly endemic countries for HB 52.7 37.9 – 66.7
Chronic renal or liver disease 22.0 4.4 – 48.4
At least one target group 58.2 47.9 – 67.7BMC Public Health 2008, 8:132 http://www.biomedcentral.com/1471-2458/8/132
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Female and male study participants did not differ in their
judgement of protective efficacy of condoms (51.8 vs.
48.2% p > 0.05).
Associations with vaccination status
Associations with vaccination status retrieved from bivar-
iate analysis are shown in figure 5. The associated factors
identified hereby were later included into a multivariate
analysis in order to detect factors independently associ-
ated with vaccination status.
Occupational risk for HB infection (OR 5.6, 95% KI 2.0–
15.8) and travel history (OR 5.4, 95% KI 2.0–14.7) were
independently associated with positive vaccination status.
Age was inversely associated with vaccination status – the
older participants were, the less likely they were to be vac-
cinated (OR for incremental age group: 0.8 (95% CI 0.6–
0.9)).
Associations with "good knowledge"
Occupational risks for HB infection (OR 11.5 (95% CI
2.5–52.8)) and positive attitude towards vaccinations in
general (OR 5.4 (95% CI 1.2–19.9)) were independently
associated with "good knowledge" (tables 4 and 5).
Female gender was negatively associated with "good
knowledge" (OR 0.5 (95% CI 0.3–0.9)), but there was an
interaction between gender and educational level (OR for
interaction term "school leaving certificate (high school
certificate/other)"* "sex (female/male)" 2.4 (95% CI 1.2–
4.6)). Furthermore, the older participants were, the less
likely they were to have "good knowledge" (table 5).
Attitudes and opinions towards the HB vaccine, and vaccines in general Figure 1
Attitudes and opinions towards the HB vaccine, and vaccines in general. (All participants and target groups for HB 
vaccination. Standardised results (sex, age group and regional distribution) for overall Germany, November 2004 (n = 412)
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Table 2: Active and passive nominations/recognition of viral hepatitis forms. Standardised results (sex, age group and regional 
distribution) Germany, November 2004 (n = 412)
Hepatitis A (%) Hepatitis B (%) Hepatitis C (%) others (%)
„Have you ever heard about one of the following hepatitis forms? 
(passive recognition)
79.3 83.4 62.5 16.9
Which kinds of viral hepatitis do you know? (active recognition) 54.3 57.7 40.5 11.2BMC Public Health 2008, 8:132 http://www.biomedcentral.com/1471-2458/8/132
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Sources of information on vaccination issues
The majority of interviewees (85%) reported to have
received information on vaccinations from their General
Practitioners (GPs) who were identified as the most
important information source for vaccine issues through-
out all age groups. Other information sources like special-
ised doctors, alternative healers, pharmacies, radio, TV
and internet were less frequently used, depending on age
group (figure 6).
Discussion
We conclude that with a reached precision of 2,9% at an
alpha level of 95% we covered a representative sample of
the major target groups for the HB vaccination within the
German population. Our study may have been biased by
the fact that migrants with poor knowledge of German
were underrepresented in the sample population. Accord-
ing to the Institute of Economic research about one third
of migrants in Germany claim not to be capable of ade-
quate German language skills [12]. This clearly represents
a weakness of our study and means a tribute to the needs
of a large-scale telephone interview.
We were able to gain insights into HB vaccine coverage
among target groups and the general population, as well
as on knowledge and attitudes regarding hepatitis B. We
observed a vaccination coverage of nearly 30% in the
overall population and of around 60% in target groups
with a high variability among the three target groups.
Despite a comparatively low response, we believe that no
major bias distorted our findings as the sampling meth-
ods allowed for recruiting a best possible sample in terms
of representativeness.
Identification of etiologic agents for HB in sample population Figure 2
Identification of etiologic agents for HB in sample population. Standardised results (sex, age group and regional distri-
bution), Germany, November 2004 (n = 412)
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Table 3: Known possible clinical symptoms or sequelae of HB infection. Standardised results (for sex, age group and regional 
distribution). Germany, November 2004 (n = 412)
Knowledge on clinical outcome of HB 
infection
% of all answers 95% CI Answers from the target group of occupation-
ally exposed
95% CI
Jaundice 83.6 79.1 – 87.2 87.1 73.1–95.8
Liver failure 67.4 62.2 – 72.4 91.8 79.5–98.4
Liver cirrhosis 60.8 55.4 – 66.0 85.6 70.4–94.3
Liver cancer 41.4 36.2 – 46.8 66.7 50.6–81.3BMC Public Health 2008, 8:132 http://www.biomedcentral.com/1471-2458/8/132
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Knowledge about protective measures to avoid HB (overall sample, target groups for HB vaccination, other population groups) Figure 4
Knowledge about protective measures to avoid HB (overall sample, target groups for HB vaccination, other 
population groups). Standardised results (sex, age group and regional distribution), November 2004 (n= 412)
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Knowledge on transmission modes for HB (all participants, target groups for HB vaccination, other participants) Figure 3
Knowledge on transmission modes for HB (all participants, target groups for HB vaccination, other partici-
pants). Standardised results (sex, age group and residency (East/West Germany) November 2004, (n= 412)
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  Possible transmission mode BMC Public Health 2008, 8:132 http://www.biomedcentral.com/1471-2458/8/132
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Since we classified a "vaccinated" person as someone
reporting at least one vaccination against HB previously,
one limitation of our study is the reliability on reported
vaccination against HB without crosschecking their vacci-
nation cards or GP records, which reportedly gives rise to
some inaccuracy [13]. Particularly, there is the risk of mis-
classification as it might be possible that vaccination
against hepatitis A was mistakenly assumed as vaccination
against HB. Moreover, the exact number of vaccinations
against HB might not have been recalled correctly or have
been mixed up in single cases. However, for reasons of
resource-effectiveness and practicability we had to rely on
self-reported data. Also, the percentage of interviewees
reporting to have had complete vaccination is quite high
and many of them must have received the combined HA/
HB vaccine; therefore, any misclassification due to mixing
up HA and HB vaccine should be rare.
In spite of the fact that we chose a rather conservative esti-
mate for "vaccination" (participants undecided about
their vaccination status were treated as "not vaccinated")
we believe that the observed vaccine coverage in the
included target groups does not meet the expectations at
all.
During our survey, we confined affiliation to target groups
for HB vaccination to such groups with either an occupa-
tional, travel-related or illness-related risk for HB infec-
tion only. Other target groups, such as men who have sex
with men (MSM) or i.v.-drug users were not taken into
account during interviews, as these individual exposures
are difficult to assess during a cross-sectional telephone
survey. These subgroups deserve more attention, and fur-
ther studies focussing on MSM or i.v.-drug users are
needed in order to estimate vaccination coverage in these
target groups, for which little data exist.
Table 4: Factors associated with positive vaccination status against HB. (Multivariate analysis) Germany, November 2004 (n = 412)
Factors associated with positive vaccination status OR 95% CI p-value
Occupational risk for HB infection 5.6 2.0–15.8 0.001
Travel risk for HB infection 5.4 2.0–14.7 0.001
Age group (incremental) 0.8 0.6–0.9 0.037
Point estimate (OR) and 95% confidence intervals of factors associated with Figure 5
Point estimate (OR) and 95% confidence intervals of factors associated with. positive vaccination status (bivariate 
analysis) Non-standardised results, Germany, November 2004 (n = 412)
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95% Confidence Interval, lower limit BMC Public Health 2008, 8:132 http://www.biomedcentral.com/1471-2458/8/132
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Occupational exposure for HB infection and travel-related
exposure were associated factors with positive vaccination
status in adults, indicating which conditions act as a fair
reason to become vaccinated. However, since all health
care workers should be vaccinated, the observed coverage
in Germany is disappointingly low. In contrast, vaccina-
tion coverage in Health care workers in Switzerland, Bel-
gium and Sweden were reported to range between 79%
and 94% (at least one full dose vaccine received) [14-16].
However, concerning the study about health workers in
Sweden the fact that health workers at risk only were
included needs mentioning. This could have led to a gen-
erally higher estimate of vaccination coverage [15].
Chronically ill people were far less often vaccinated than
travellers or occupationally exposed persons, which sug-
gests that health care messages for these subgroups have
not come across – be this founded in poor counselling or
poor adherence. Also, a lack of knowledge among health
staff might explain the low vaccination coverage of the
chronically ill.
We confined the general term "good knowledge" on HB to
a combined good knowledge about the major transmis-
sion routes, protective measures and types of HB. This
rather specific definition for good knowledge could have
lead to an underestimation of knowledge in the German
population. However, this term was used for our model
only but still particular subgroups of knowledge have nev-
ertheless been presented within the descriptive analysis.
Our results on transmission risks for HB show that within
the German population little knowledge exists about the
fact that HB is transmitted sexually. This finding complies
Sources of information on vaccine related issues by age group Figure 6
Sources of information on vaccine related issues by age group. Standardised results (sex, age group and regional distri-
bution), Germany, November 2004 (n = 412)
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Table 5: Independent predictors of "good knowledge" on HB. (Multivariate analysis) Germany, November 2004, (n = 412)
Factors associated with good knowledge on HB OR 95% CI p-value
Occupational risk for HB infection 11.5 2.5 – 52.8 0.002
Positive attitude towards vaccinations in general 5.4 1.2 – 19.9 0.021
Increasing age group 0.8 0.6 – 0.9 0.008
Female gender 0.5 0.3 – 0.9 0.019
Interaction term [education level * sex] 2.4 1.2 – 4.6 0.016BMC Public Health 2008, 8:132 http://www.biomedcentral.com/1471-2458/8/132
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with the fact that condoms were less well known to pro-
tect from HB infection than hygiene measures and vacci-
nation.
Age was negatively associated with "good knowledge" in
our study which may reflect a better general health related
knowledge in the young, or it may be due to employees
such as health care workers with a better expertise. Fur-
thermore, the fact that since 1995 HB vaccination is rec-
ommended for all newborns and adolescents may have
caused an increased awareness in those who are now
young adults.
Corresponding to better knowledge among the young, age
was inversely associated with vaccination status – the
older participants were, the less likely they were to be vac-
cinated. This finding corresponds to a recent study on HB
vaccination status among adult blood donors in Ger-
many, where younger age was significantly associated
with a higher HB vaccine coverage [17]. Also, this might
be explained by the recent vaccine recommendation pol-
icy to vaccinate infants, children and adolescents against
HB or may display a generally better acceptance of the HB
vaccination [8].
Our findings are supported by preliminary results of
another recent study on knowledge about hepatitis B in
Germany which likewise revealed a clear association of
social status and knowledge of HB as well as a negative
association of age and knowledge of HB [18]. We identi-
fied a negative association of female gender and knowl-
edge about HB, although the association could be at least
partly explained by an interaction between lesser school
education and female sex. Also, a generally better knowl-
edge of HB among MSM and iv drug users (more likely
men) in our sample may have confounded our finding
that men had a better knowledge of HB than women. In
our sample population of 412 persons we expect for
instance around 12 MSM (5% of 247 men in the sample
population). Nevertheless, this finding is in contrary to
the results of another German study where knowledge on
transmission of disease and the use of preventive meas-
ures as immunisation was found better in females (78%
in females versus 69% in males, p = 0.05) [19]. Even after
taking into account that the latter study involved students
only and might therefore be biased by a generally higher
education level it remains unclear why in our study
knowledge was found better in men.
We observed a predominantly good appreciation of the
protective effectiveness and safety of the HB vaccine and
therefore assume that the general acceptance of HB vacci-
nation within the German population is basically good;
educational programmes on HB and vaccines are likely to
lead to higher vaccination coverage in target groups for
HB vaccine.
It has been shown that health-educational interventions
regarding knowledge of HB risk factors and protective
measures in students could measurably increase knowl-
edge on HB and acceptance of vaccination [20]. In
another study, educational measures about HB were par-
ticularly effective in influencing vaccination attitude in
men who have sex with men when these programmes
were able to increase the individual risk perception [21].
It can be hypothesized that this mechanism would work
in other target groups, too.
In designing health-educational programmes one needs
to bear in mind the low awareness of sexual transmission
modes for HB in the general population, and that the pro-
tective effects of condom use, besides vaccination, should
therefore be highlighted.
As poorer knowledge was found among higher age
groups, information campaigns on HB should not only
focus on the young, although they need to be tailored spe-
cifically for adolescents and young adults, in whom the
HB incidence is still highest [6,10].
HB vaccine uptake in those for whom HB vaccination is
recommended but who tend to remain unvaccinated
despite existing policies needs to be increased. This can be
achieved by awareness campaigns and counselling.
As GPs and family doctors play a key role as a source for
information, future educational measures concerning HB
should be closely coordinated with the GP level of ambu-
latory care. It can be expected that counselling for vaccine
issues could be performed far more efficiently by German
GPs if they would be rewarded appropriately. Besides time
restraints and poor payment, possible other reasons for
insufficient information transfer at the GP level in Ger-
many should be investigated more thoroughly.
Conclusion
Knowledge about HB and its risk factors in Germany was
far below expectations and needs to be improved. Also,
vaccination coverage in target groups was unsatisfactory.
We conclude that educational measures could lead to a
higher vaccine uptake in adult target groups.
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